{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:53:31Z","timestamp":1792601611838,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10787-024-01590-0","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T10:03:47Z","timestamp":1730196227000},"page":"485-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cyclosporin for the treatment of Stevens\u2013Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): a systematic review of observational studies and clinical trials focusing on single therapy, combination therapy, and comparative assessments"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5978-758X","authenticated-orcid":false,"given":"Amirhossein","family":"Nazerian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5878-9778","authenticated-orcid":false,"given":"Alireza","family":"Jafarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobina","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-4429","authenticated-orcid":false,"given":"Azadeh","family":"Goodarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"issue":"5","key":"1590_CR1","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1046\/j.1523-1747.2002.01709.x","volume":"118","author":"WI Al-Daraji","year":"2002","unstructured":"Al-Daraji WI, Abed FA, Al-Shaibani A et al (2002) Localization of calcineurin\/NFAT in human skin and psoriasis and inhibition of calcineurin\/NFAT activation in human keratinocytes by cyclosporin A. J Invest Dermatol 118(5):779\u2013788. https:\/\/doi.org\/10.1046\/j.1523-1747.2002.01709.x","journal-title":"J Invest Dermatol"},{"issue":"10","key":"1590_CR2","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1002\/eji.1830241032","volume":"24","author":"A Anel","year":"1994","unstructured":"Anel A, Simon MM, Bessoles S et al (1994) T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A. Eur J Immunol 24(10):2469\u20132476. https:\/\/doi.org\/10.1002\/eji.1830241032","journal-title":"Eur J Immunol"},{"issue":"3","key":"1590_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","volume":"48","author":"JM Ar\u00e9valo","year":"2000","unstructured":"Ar\u00e9valo JM, L\u00f3pez-Mu\u00f1oz A, Paniagua M et al (2000) Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 48(3):473\u2013478. https:\/\/doi.org\/10.1097\/00005373-200003000-00017","journal-title":"J Trauma"},{"issue":"1","key":"1590_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4103\/idoj.IDOJ_326_20","volume":"12","author":"M Balai","year":"2021","unstructured":"Balai M, Bansal A, Gupta S et al (2021) Cyclosporine in stevens-johnson syndrome and toxic epidermal necrolysis: experience from a tertiary care centre of South Rajasthan. Indian Dermatol Online J 12(1):116\u2013122. https:\/\/doi.org\/10.4103\/idoj.IDOJ_326_20","journal-title":"Indian Dermatol Online J"},{"issue":"8","key":"1590_CR5","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.autrev.2008.06.004","volume":"7","author":"AT Borchers","year":"2008","unstructured":"Borchers AT, Keen CL, Atkinson JS et al (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 7(8):598\u2013605. https:\/\/doi.org\/10.1016\/j.autrev.2008.06.004","journal-title":"Autoimmun Rev"},{"issue":"10","key":"1590_CR6","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1159\/000531366","volume":"184","author":"S Cekic","year":"2023","unstructured":"Cekic S, Mardini H, Watanabe T et al (2023) A comprehensive assessment of long-term complications in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Int Arch Allergy Immunol 184(10):994\u20131002. https:\/\/doi.org\/10.1159\/000531366","journal-title":"Int Arch Allergy Immunol"},{"issue":"12","key":"1590_CR7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/nm.1884","volume":"14","author":"WH Chung","year":"2008","unstructured":"Chung WH, Wang HW, Huang SP et al (2008) Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14(12):1343\u20131350. https:\/\/doi.org\/10.1038\/nm.1884","journal-title":"Nat Med"},{"issue":"1","key":"1590_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14656","volume":"34","author":"SN Emadi","year":"2021","unstructured":"Emadi SN, Baghery A, Nasiri S et al (2021) Challenges in the treatment of a patient with toxic epidermal necrolysis associated with COVID-19: a case report. Dermatol Ther 34(1):e14656. https:\/\/doi.org\/10.1111\/dth.14656","journal-title":"Dermatol Ther"},{"issue":"6","key":"1590_CR9","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s13555-024-01180-6","volume":"14","author":"F Erduran","year":"2024","unstructured":"Erduran F, Korkusuz P, Karaca D et al (2024) Evaluation of the factors influencing mortality in patients with stevens-johnson syndrome and toxic epidermal necrolysis: A Multicenter Study of 166 Patients. Dermatol Ther (Heidelb) 14(6):1547\u20131560. https:\/\/doi.org\/10.1007\/s13555-024-01180-6","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1590_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4249","volume":"9","author":"S Farajzadeh","year":"2021","unstructured":"Farajzadeh S, Ahramiyanpour N (2021) Which immunosuppressive drug is preferred in the treatment of toxic epidermal necrolysis during COVID-19 outbreak? Clin Case Rep 9(5):e04249. https:\/\/doi.org\/10.1002\/ccr3.4249","journal-title":"Clin Case Rep"},{"issue":"4","key":"1590_CR11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jaad.2011.12.014","volume":"67","author":"BF Firoz","year":"2012","unstructured":"Firoz BF, Morgan A, Delman A et al (2012) Toxic epidermal necrolysis: five years of treatment experience from a burn unit. J Am Acad Dermatol 67(4):630\u2013635. https:\/\/doi.org\/10.1016\/j.jaad.2011.12.014","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1590_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1001\/archderm.136.3.323","volume":"136","author":"I Garc\u00eda-Doval","year":"2000","unstructured":"Garc\u00eda-Doval I, Serrano-Falc\u00f3n C, Llamas-Velasco M et al (2000) Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 136(3):323\u2013327. https:\/\/doi.org\/10.1001\/archderm.136.3.323","journal-title":"Arch Dermatol"},{"issue":"10","key":"1590_CR13","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.jid.2017.05.022","volume":"137","author":"C Gonz\u00e1lez-Herrada","year":"2017","unstructured":"Gonz\u00e1lez-Herrada C, Gonz\u00e1lez-V\u00e1zquez M, V\u00e1zquez-Peri\u00f1\u00e1n C et al (2017) Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. J Invest Dermatol 137(10):2092\u20132100. https:\/\/doi.org\/10.1016\/j.jid.2017.05.022","journal-title":"J Invest Dermatol"},{"issue":"9","key":"1590_CR14","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s00403-006-0639-3","volume":"297","author":"G Gravante","year":"2006","unstructured":"Gravante G, Azzena G, Goteri G et al (2006) Apoptotic cell death in toxic epidermal necrolysis: the Fas ligand assumption. Arch Dermatol Res 297(9):430\u2013431. https:\/\/doi.org\/10.1007\/s00403-006-0639-3","journal-title":"Arch Dermatol Res"},{"key":"1590_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/f1000research.24748.1","volume":"9","author":"A Hasegawa","year":"2020","unstructured":"Hasegawa A, Abe R (2020) Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res 9:1\u20138. https:\/\/doi.org\/10.12688\/f1000research.24748.1","journal-title":"F1000Res"},{"issue":"1","key":"1590_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4103\/ijd.ijd_612_23","volume":"69","author":"NC Jangid","year":"2024","unstructured":"Jangid NC, Joshi A, Gawande T et al (2024) Clinico-therapeutic study of Stevens Johnson syndrome-toxic epidermal necrolysis and prognostic significance of SCORTEN in Indian patients. Indian J Dermatol 69(1):24\u201331. https:\/\/doi.org\/10.4103\/ijd.ijd_612_23","journal-title":"Indian J Dermatol"},{"issue":"5","key":"1590_CR17","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jaad.2014.07.016","volume":"71","author":"MG Kirchhof","year":"2014","unstructured":"Kirchhof MG, Smith HE, van Mook WN et al (2014) Retrospective review of Stevens-Johnson syndrome\/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol 71(5):941\u2013947. https:\/\/doi.org\/10.1016\/j.jaad.2014.07.016","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1590_CR18","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1001\/jamadermatol.2021.3154","volume":"157","author":"K Kridin","year":"2021","unstructured":"Kridin K, Comaneshter D, Cohen AD (2021) Assessment of treatment approaches and outcomes in Stevens-Johnson syndrome and toxic epidermal necrolysis: insights from a Pan-European Multicenter Study. JAMA Dermatol 157(10):1182\u20131190. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3154","journal-title":"JAMA Dermatol"},{"key":"1590_CR19","unstructured":"Labib A, Milroy C (2023) Toxic epidermal necrolysis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574530\/"},{"issue":"9","key":"1590_CR20","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1097\/00007890-199911150-00007","volume":"68","author":"JI Lee","year":"1999","unstructured":"Lee JI, Vanichanan J, Dyer D et al (1999) Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B. Transplantation 68(9):1255\u20131263. https:\/\/doi.org\/10.1097\/00007890-199911150-00007","journal-title":"Transplantation"},{"issue":"1","key":"1590_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaad.2016.07.048","volume":"76","author":"HY Lee","year":"2017","unstructured":"Lee HY, Kim HS, Lee JH et al (2017) Cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis: retrospective analysis of a cohort treated in a specialized referral center. J Am Acad Dermatol 76(1):106\u2013113. https:\/\/doi.org\/10.1016\/j.jaad.2016.07.048","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1590_CR22","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.jaip.2018.10.053","volume":"7","author":"RJ Lehloenya","year":"2019","unstructured":"Lehloenya RJ, Dlamini Z, Rukunga G et al (2019) Lower-than-predicted mortality in a predominantly HIV-infected population with epidermal necrolysis regardless of HIV status: implications and challenges for interventional studies. J Allergy Clin Immunol Pract 7(5):1653\u20131655. https:\/\/doi.org\/10.1016\/j.jaip.2018.10.053","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1590_CR23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.bcp.2019.03.022","volume":"163","author":"AM Liddicoat","year":"2019","unstructured":"Liddicoat AM, Lavelle EC (2019) Modulation of innate immunity by cyclosporine A. Biochem Pharmacol 163:472\u2013480. https:\/\/doi.org\/10.1016\/j.bcp.2019.03.022","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"1590_CR24","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4103\/ijdvl.IJDVL_201_16","volume":"83","author":"S Mohanty","year":"2017","unstructured":"Mohanty S, Prasad S, Roy D et al (2017) Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson syndrome\/toxic epidermal necrolysis: a record-based study. Indian J Dermatol Venereol Leprol 83(3):312\u2013316. https:\/\/doi.org\/10.4103\/ijdvl.IJDVL_201_16","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"12","key":"1590_CR25","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/nm1208-1311","volume":"14","author":"BJ Nickoloff","year":"2008","unstructured":"Nickoloff BJ (2008) Saving the skin from drug-induced detachment. Nat Med 14(12):1311\u20131313. https:\/\/doi.org\/10.1038\/nm1208-1311","journal-title":"Nat Med"},{"issue":"4","key":"1590_CR26","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamadermatol.2018.5605","volume":"155","author":"MH Noe","year":"2019","unstructured":"Noe MH, Rampersad K, Manolya N et al (2019) Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis\u2014ABCD-10. JAMA Dermatol 155(4):448\u2013454. https:\/\/doi.org\/10.1001\/jamadermatol.2018.5605","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1590_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.burns.2023.08.009","volume":"50","author":"DK Ozhathil","year":"2024","unstructured":"Ozhathil DK, Jameson M, Gopal D et al (2024) A retrospective analysis of mortality risk and immunosuppressive therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome using the TriNetX research network. Burns 50(1):75\u201386. https:\/\/doi.org\/10.1016\/j.burns.2023.08.009","journal-title":"Burns"},{"issue":"6","key":"1590_CR28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s00403-005-0607-3","volume":"297","author":"P Paquet","year":"2005","unstructured":"Paquet P, Robert M, Trouette R et al (2005) Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. Arch Dermatol Res 297(6):266\u2013273. https:\/\/doi.org\/10.1007\/s00403-005-0607-3","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"1590_CR29","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s13346-019-00650-1","volume":"9","author":"D Patel","year":"2019","unstructured":"Patel D, Wairkar S (2019) Recent advances in cyclosporine drug delivery: challenges and opportunities. Drug Deliv Transl Res 9(6):1067\u20131081. https:\/\/doi.org\/10.1007\/s13346-019-00650-1","journal-title":"Drug Deliv Transl Res"},{"issue":"2","key":"1590_CR30","doi-asserted-by":"publisher","first-page":"WC10","DOI":"10.7860\/JCDR\/2023\/60197.17530","volume":"17","author":"L Patel","year":"2023","unstructured":"Patel L, Kamath G, Lobo S et al (2023) Effectiveness of corticosteroids alone versus corticosteroids and cyclosporine in the management of patients with severe cutaneous drug reaction. J Clin Diagn Res 17(2):WC10\u2013WC13. https:\/\/doi.org\/10.7860\/JCDR\/2023\/60197.17530","journal-title":"J Clin Diagn Res"},{"issue":"6","key":"1590_CR31","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jid.2017.12.034","volume":"138","author":"F Poizeau","year":"2018","unstructured":"Poizeau F, Duong TA, Le Cleach L et al (2018) Cyclosporine for epidermal necrolysis: absence of beneficial effect in a retrospective cohort of 174 patients-exposed\/unexposed and propensity score-matched analyses. J Invest Dermatol 138(6):1293\u20131300. https:\/\/doi.org\/10.1016\/j.jid.2017.12.034","journal-title":"J Invest Dermatol"},{"issue":"8","key":"1590_CR32","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/j.1365-2230.2010.03826.x","volume":"35","author":"R Rajaratnam","year":"2010","unstructured":"Rajaratnam R, Loffler F, McGrath M et al (2010) Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre. Clin Exp Dermatol 35(8):853\u2013862. https:\/\/doi.org\/10.1111\/j.1365-2230.2010.03826.x","journal-title":"Clin Exp Dermatol"},{"issue":"19","key":"1590_CR33","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","volume":"331","author":"JC Roujeau","year":"1994","unstructured":"Roujeau JC, Stern RS (1994) Severe adverse cutaneous reactions to drugs. N Engl J Med 331(19):1272\u20131285. https:\/\/doi.org\/10.1056\/NEJM199411103311906","journal-title":"N Engl J Med"},{"issue":"4","key":"1590_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/ACI.0000000000000914","volume":"23","author":"Y Saito","year":"2023","unstructured":"Saito Y, Abe R (2023) New insights into the diagnosis and management of Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Opin Allergy Clin Immunol 23(4):271\u2013278. https:\/\/doi.org\/10.1097\/ACI.0000000000000914","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"2","key":"1590_CR35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/BCR.0b013e31820aafbc","volume":"32","author":"P Sekula","year":"2011","unstructured":"Sekula P, Dunant A, Mockenhaupt M et al (2011) Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res 32(2):237\u2013245. https:\/\/doi.org\/10.1097\/BCR.0b013e31820aafbc","journal-title":"J Burn Care Res"},{"issue":"4","key":"1590_CR36","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.57862","volume":"16","author":"A Senda","year":"2024","unstructured":"Senda A, Fushimi K, Morishita K (2024) Effect of early cyclosporine treatment on survival in Stevens-Johnson syndrome and toxic epidermal necrolysis. Cureus 16(4):e57862. https:\/\/doi.org\/10.7759\/cureus.57862","journal-title":"Cureus"},{"issue":"2","key":"1590_CR37","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2018.09.063","volume":"85","author":"R Shah","year":"2021","unstructured":"Shah R, Chen ST, Kroshinsky D (2021) Use of cyclosporine for the treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis. J Am Acad Dermatol 85(2):512\u2013513. https:\/\/doi.org\/10.1016\/j.jaad.2018.09.063","journal-title":"J Am Acad Dermatol"},{"key":"1590_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2023-324901(Inpress)","author":"N Sharma","year":"2024","unstructured":"Sharma N, Mohanan S, Mohanan R et al (2024) Evaluation of adjuvant role of topical cyclosporine 1% in acute Stevens-Johnson syndrome: a randomized control trial. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/bjo-2023-324901(Inpress)","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"1590_CR39","doi-asserted-by":"publisher","first-page":"686","DOI":"10.4103\/0378-6323.116738","volume":"79","author":"GK Singh","year":"2013","unstructured":"Singh GK, Chatterjee M, Verma R (2013) Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian J Dermatol Venereol Leprol 79(5):686\u2013692. https:\/\/doi.org\/10.4103\/0378-6323.116738","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1590_CR40","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/230386","volume":"2012","author":"D Tedesco","year":"2012","unstructured":"Tedesco D, Haragsim L (2012) Cyclosporine: a review. J Transplant 2012:230386. https:\/\/doi.org\/10.1155\/2012\/230386","journal-title":"J Transplant"},{"issue":"10","key":"1590_CR41","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/1346-8138.15490","volume":"47","author":"I Torres-Navarro","year":"2020","unstructured":"Torres-Navarro I, Arrebola-Moreno M, Mart\u00edn-Gonz\u00e1lez E et al (2020) Accuracy of SCORTEN and ABCD-10 to predict mortality and the influence of renal function in Stevens-Johnson syndrome\/toxic epidermal necrolysis. J Dermatol 47(10):1182\u20131186. https:\/\/doi.org\/10.1111\/1346-8138.15490","journal-title":"J Dermatol"},{"issue":"4","key":"1590_CR42","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","volume":"163","author":"L Valeyrie-Allanore","year":"2010","unstructured":"Valeyrie-Allanore L, Mockenhaupt M, Goffin V et al (2010) Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 163(4):847\u2013853. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09863.x","journal-title":"Br J Dermatol"},{"key":"1590_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.949520","volume":"9","author":"L Wang","year":"2022","unstructured":"Wang L, Yang L, Zhang Z et al (2022) Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review of PubMed\/MEDLINE case reports from 1980 to 2020. Front Med (Lausanne) 9:949520. https:\/\/doi.org\/10.3389\/fmed.2022.949520","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"1590_CR44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1046\/j.1523-1747.2000.00037.x","volume":"115","author":"P Wehrli","year":"2000","unstructured":"Wehrli P, B\u00fctikofer L, Sidler M et al (2000) Death receptors in cutaneous biology and disease. J Invest Dermatol 115(2):141\u2013148. https:\/\/doi.org\/10.1046\/j.1523-1747.2000.00037.x","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1590_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.ackd.2005.11.001","volume":"13","author":"D Williams","year":"2006","unstructured":"Williams D, Haragsim L (2006) Calcineurin nephrotoxicity. Adv Chronic Kidney Dis 13(1):47\u201355. https:\/\/doi.org\/10.1053\/j.ackd.2005.11.001","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"1590_CR46","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/1346-8138.16369","volume":"49","author":"R Yu","year":"2022","unstructured":"Yu R, Zhang T, Zhou Y et al (2022) Combined use of cyclosporine in the treatment of Stevens-Johnson syndrome\/toxic epidermal necrolysis. J Dermatol 49(6):629\u2013636. https:\/\/doi.org\/10.1111\/1346-8138.16369","journal-title":"J Dermatol"},{"issue":"1","key":"1590_CR47","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/ajd.13958","volume":"64","author":"H Zou","year":"2023","unstructured":"Zou H, Daveluy S (2023) Toxic epidermal necrolysis and Stevens-Johnson syndrome after COVID-19 infection and vaccination. Australas J Dermatol 64(1):e1\u2013e10. https:\/\/doi.org\/10.1111\/ajd.13958","journal-title":"Australas J Dermatol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01590-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-024-01590-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01590-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:04:59Z","timestamp":1740107099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-024-01590-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1590"],"URL":"https:\/\/doi.org\/10.1007\/s10787-024-01590-0","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors of the article have no conflicts of interest. The authors declare that the manuscript is an honest, accurate, and transparent. No important aspect of the study is omitted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The researchers were committed and adhered to the principles of the Helsinki Convention and the Ethics Committee of the Iran University of Medical Sciences in all stages.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}